Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Oct 07, 2024

BUY
$12.63 - $24.47 $16.7 Million - $32.3 Million
1,321,219 New
1,321,219 $31.2 Million
Q4 2023

Feb 12, 2024

BUY
$12.63 - $24.47 $16.7 Million - $32.3 Million
1,321,219 New
1,321,219 $31.2 Million

Others Institutions Holding CBAY

About CymaBay Therapeutics, Inc.


  • Ticker CBAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,677,904
  • Description
  • CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...
More about CBAY
Track This Portfolio

Track Lord, Abbett & Co. LLC Portfolio

Follow Lord, Abbett & Co. LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lord, Abbett & Co. LLC with notifications on news.